Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study reveals how COVID-19 vaccines shield us

NCT ID NCT06761612

Knowledge-focused Sponsor: Biomedical Advanced Research and Development Authority Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study involved over 2,500 people of all ages to find out which immune responses best predict protection against COVID-19 after vaccination. Researchers also tested whether local pharmacies could collect blood and nasal samples effectively. The goal is to improve future vaccine monitoring and public health strategies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

2,519 people

The number who actually took part.

Started

Oct 2024

Finished

May 2026

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prior to enrollment in this study, participants will receive a federally licensed and authorized vaccine, manufactured by Pfizer-BioNTech or Moderna, for the prevention of COVID-19. Each participant will complete a pre-screener questionnaire which will collect information to confirm the participant's eligibility. Upon passing the pre-screener, the participant will complete their electronic consent form and will be enrolled in the study within 72 hours of their vaccination with blood collected to establish baseline for humoral immune marker. A subset of total enrollment, a cohort of 80 participants, will also enroll in the PBMC cohort; participants in the PBMC cohort will enroll in the study within 24 hours of their vaccination with blood collected to establish baseline immune marker levels.

Ages

3 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. People ≥3 years of age at time of enrollment. 2. Willing and able to provide informed consent, or assent in pediatric population, if appropriate, prior to initiation of study procedures. 3. Able to understand and comply with planned study procedures. 4. Available for all study data collection points. 5. Receipt of the most recent FDA-licensed and authorized COVID-19 vaccine (i.e., the 2024-2025 Moderna COVID-19 vaccine or the 2024-2025 Pfizer-BioNTech COVID-19 vaccine which includes the KP.2 strain of the JN.1-lineage vaccine), as recommended by the FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) and outlined in the FDA's updated guidance, administered within 3 days of enrollment. PBMC cohort only: People ages ≥18 years at time of enrollment. Available for first blood sample collection within 1 day of vaccine. Exclusion Criteria: 1. Currently participating or plans to participate in another clinical trial involving an investigational product before completing this study. 2. Planned to receive another COVID-19 vaccine within 180 days. 3. Receipt of COVID-19 vaccination within 180 days prior to current vaccination. 4. Receipt of Shingrix vaccine in the 28 days prior to the COVID-19 vaccination or planned receipt of Shingrix vaccine within 28 days after receipt of COVID-19 vaccination. 5. Self-report of recently confirmed COVID-19 infection within 30 days. 6. Any disease or medical condition that, in the opinion of the principal investigator or sub-investigator, is a contraindication to study participation. PBMC cohort only: Confirmed positive urine pregnancy test at study visits per Schedule of Activities.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID-19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID-19

Contacts and locations

Locations

  • Walgreens - 1445 W Craig Rd

    North Las Vegas, Nevada, 89032, United States

  • Walgreens - 15100 W 87th Street Pkwy

    Lenexa, Kansas, 66219, United States

  • Walgreens - 1554 E 55th St

    Chicago, Illinois, 60615, United States

  • Walgreens - 17811 E US Highway 24

    Independence, Missouri, 64056, United States

  • Walgreens - 1919 W Gray St

    Houston, Texas, 77019, United States

  • Walgreens - 215 Beach St

    Malden, Massachusetts, 02148, United States

  • Walgreens - 2630 NE Vivion

    Kansas City, Missouri, 64119, United States

  • Walgreens - 3218 Atlantic Ave

    Atlantic City, New Jersey, 08401, United States

  • Walgreens - 3298 S John Young Pkwy

    Kissimmee, Florida, 34746, United States

  • Walgreens - 3316 Avenue H

    Rosenberg, Texas, 77471, United States

  • Walgreens - 3845 Broadway Blvd

    Kansas City, Missouri, 64111, United States

  • Walgreens - 420 N Frazier St

    Conroe, Texas, 77301, United States

  • Walgreens - 4385 S Archer Ave

    Chicago, Illinois, 60632, United States

  • Walgreens - 520 Convery Blvd

    Perth Amboy, New Jersey, 08861, United States

  • Walgreens - 6401 W Charleston Blvd

    Las Vegas, Nevada, 89146, United States

  • Walgreens - 7251 Lake St

    River Forest, Illinois, 60305, United States

  • Walgreens - 7440 FM 1960 Rd E

    Humble, Texas, 77346, United States

  • Walgreens - 7500 Metcalf Ave

    Overland Park, Kansas, 66204, United States

  • Walgreens - 811 Madison St

    Oak Park, Illinois, 60302, United States

  • Walgreens - 8430 Broadway St

    Pearland, Texas, 77584, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.